Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.

Wils, J A; Bliss, J M; Marty, M; Coombes, G; Fontaine, C; Morvan, F; Olmos, T; Pérez-López, F R; Vassilopoulos, P; Woods, E; Coombes, R C

Wils, J A; Bliss, J M; Marty, M; Coombes, G; Fontaine, C; Morvan, F; Olmos, T; Pérez-López, F R; Vassilopoulos, P; Woods, E; Coombes, R C.

Affiliation

Wils JA; Laurentius Hospital, Roermond, The Netherlands.

J Clin Oncol ; 17(7): 1988-98, 1999 Jul.

Article in En | MEDLINE | ID: mdl-10561249

Subject(s)

Antineoplastic Agents, Hormonal/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Breast Neoplasms/drug therapy; Tamoxifen/administration & dosage; Adult; Age Factors; Aged; Breast Neoplasms/mortality; Breast Neoplasms/pathology; Disease-Free Survival; Epirubicin/administration & dosage; Female; Humans; London/epidemiology; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local/drug therapy; Neoplasm Recurrence, Local/epidemiology; Neoplasms, Second Primary/epidemiology; Paris/epidemiology; Postmenopause; Proportional Hazards Models; Survival Rate

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Tamoxifen / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Antineoplastic Agents, Hormonal Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Year: 1999 Type: Article

Search on Google

XML

PubMed Links